Per cent absorbed time plots derived from blood level and/or urinary excretion data.
about
Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluentsControlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studiesIn Vitro and In Vivo Evaluations of PLGA Microspheres Containing NalmefenePharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam.Bioavailability of commercial tetracycline products.Paracellular absorption is relatively low in the herbivorous Egyptian spiny-tailed lizard, Uromastyx aegyptia.Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration.Hair follicles contribute significantly to penetration through human skin only at times soon after application as a solvent deposited solid in man.Properties of the recirculation model: calculation of the amount of drug in the body from blood concentration data, with application to absorption rate calculations.Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children.Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article.An overview of preparation and evaluation sustained-release injectable microspheres.In vitro-in vivo correlations: general concepts, methodologies and regulatory applications.System approaches in pharmacokinetics: I. Basic concepts.The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation.Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century.Rho Chi Lecture. Some contributions and guidance for future graduate students.Study of the in vitro-in vivo correlation of Danshensu and protocatechuic aldehyde in a two-step release system.Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.In vitro-in vivo correlations: tricks and traps.Fasting and nonfasting blood ethanol concentrations following repeated oral administration of ethanol to one adult male subject.IVIVC from Long Acting Olanzapine Microspheres.Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile.Pharmacokinetic and pharmacodynamic aspects of artelinic acid in rodents.Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method.Thermal sintering: a novel technique used in the design, optimization and biopharmaceutical evaluation of propranolol HCl gastric floating tablets.Influence of feeding on the bioavailability of ronidazole prolonged-release formulations in pigeons.Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man.A pharmacokinetic method for designing prolonged-release formulations--propoxyphene hydrochloride.In vivo-in vitro correlation for amoxicillin trihydrate 1000 mg dispersible tablet.Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects.Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses.Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization, in vitro/in vivo characterization, and pharmacokinetics in human volunteers.Application of an in vitro DDASS to evaluate oral absorption of two chemicals simultaneously: establishment of a level A in vitro-in vivo correlation.Impact of microparticle formulation approaches on drug burst release: a level A IVIVC.
P2860
Q28366172-25D52FF7-E4F3-4138-8933-B759E1129125Q28542853-2B18BEC7-DE19-4A60-81C5-829C33308EFDQ28546982-CAF670EA-3A76-4DB5-90EE-8F618540834EQ30449218-31192784-DF59-43E3-9779-D9EF2C8D1D20Q33406712-09831A0D-6852-4E6A-A937-4206FFE2F4FFQ34451329-EFEF2B5F-1DA7-4DE4-9CA1-3683C9D49448Q34676367-59FD9E3F-11BA-4989-9180-EB28F25FA8AFQ35130421-B6119F63-51BB-480F-97F1-DB0D469EDB77Q35624593-709D008F-21FC-4CDE-8F12-BE7B753B0102Q36658943-9672ED49-915C-4B84-B45B-00525628B518Q36755819-283F66B0-8FD4-441A-AA9B-401DF4A5DDCEQ37906417-42A35721-AE1A-4B52-A070-DBFA868B1F02Q38058839-5493B2F6-4F09-4C8F-A650-C3DC01DD11AFQ38541574-1691DA7B-2EDE-47E2-95BD-D3C515386E01Q39634069-CBE5EFE8-D753-4F86-97AE-9209509C191BQ39822036-54E5724A-A661-4BF0-93E5-CB89CF04F91EQ40749507-82574B90-0018-4EFF-B60D-5F05F90AB0ADQ41028432-29C8175D-84D3-40C3-9062-39CB14293FABQ41512256-295574C7-40C4-486D-AD5A-2506ACD6F4D6Q41724551-655FAD66-B239-4C34-A6B6-8E729EF86A5BQ41887534-2FDEA7EE-B3DD-4716-9A6D-F190602F6E3BQ41905533-32736D79-4CBB-49ED-B5AA-41C6A9980BA4Q41937906-2CFE8033-3D6F-4741-AE3C-9976103E730FQ42596512-332790B2-B7C7-4ADC-8C7C-00060B297950Q42635952-6ACC6C85-53DF-4366-B8E5-06AFFCD271A2Q43201529-1AB39B45-B98D-4DFA-A458-3715CCE34EE7Q43712645-B641842C-7FB0-4F54-84DF-9831CD038FD0Q43836005-AB87F979-0599-4C13-A57B-6483FED9A71AQ43877342-72816C8B-B00E-4F2A-9131-627065BEFD4DQ44476298-76CC0134-B5EB-46FE-9CE7-A2FCFFF7E6EBQ44794980-54A8C8FA-5EFE-4B4E-B9C9-FCD9E8BBD60EQ44954088-4645D8C3-3ABD-493E-887F-9D33F3BF1F9FQ45102091-B9E29B42-B6FD-44F7-B9C1-434CFFBB31F9Q45190685-6F14954A-47C4-4E17-BCFE-29CBA522FD5DQ46054293-C8ACC4E2-7D56-4A70-A60D-89F85100CA1AQ46146875-64D34B95-DA81-4075-B3AD-6A2C9817DB48Q46384348-508715F2-15E8-47A3-98FC-E933A98C2EDDQ46503895-A728D385-022D-40C4-A00E-DCB279A1754FQ46687702-F9003157-0E34-44CA-8608-F1609B2D2B0CQ46897568-78356BD9-112A-4D3F-B24D-39A606A07E41
P2860
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
description
1963 nî lūn-bûn
@nan
1963 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1963 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1963年の論文
@ja
1963年論文
@yue
1963年論文
@zh-hant
1963年論文
@zh-hk
1963年論文
@zh-mo
1963年論文
@zh-tw
1963年论文
@wuu
name
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@ast
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@en
type
label
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@ast
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@en
prefLabel
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@ast
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@en
P356
P1476
Per cent absorbed time plots derived from blood level and/or urinary excretion data.
@en
P2093
P304
P356
10.1002/JPS.2600520629
P407
P577
1963-06-01T00:00:00Z